TRDA
Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing intracellular therapeutics using its proprietary Endosomal Escape Vehicle (EEV) platform. Headquartered in Boston, the company aims to deliver therapeutics designed to reach disease targets inside cells across neuromuscular, ocular, metabolic, and immunological diseases, with a lead emphasis on Duchenne muscular dystrophy programs. Their portfolio includes RNA-, antibody-, and enzyme-based approaches, with ongoing clinical studies exploring treatments for previously intractable intracellular targets.
No recent news for this company.
No recent deals for this company.